Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the US EoE market ...

The Victoria, B.C.-based company is developing EP-104IAR for osteoarthritis pain and a new formulation for eosinophilic ...

At the same time, more than half of the US-listed stocks covered by Morningstar that reported earnings as of Aug. 11 beat ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Collection Group Methodology: How TIME and Statista Determined the World's Most Sustainable Companies of 2025 In the fight against climate change, companies are navigating compounding ...